{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:45:36Z","timestamp":1787877936748,"version":"build-2784847793"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>PRODUCTS with janus kinase (JAK) inhibition have been shown to promote hair regrowth in patients with alopecia areata (AA). To guide drug\u2010approval and treatment decisions, it is important to understand patients' willingness to accept the potential risks of JAK inhibition in exchange for potential benefits. We quantified the treatment preferences of adult (\u226518\u2009years) and adolescent patients (12\u201317\u2009years) with AA in the US and Europe to determine the trade\u2010offs they are willing to make between benefits and risks. Preferences for oral AA treatment attributes were elicited using a discrete choice experiment consisting of 12 tasks in which patients chose between two hypothetical treatment alternatives and no treatment. Benefits included the probability of 80%\u2013100% scalp hair regrowth (Severity of Alopecia Tool score\u2009\u2264\u200920) and achieving moderate\u2010to\u2010normal eyebrow and eyelash hair. Treatment\u2010related risks included 3\u2010year probabilities of serious infection, cancer, and blood clots. Preference estimates were used to calculate the maximum level of each risk that patients were willing to accept for increases in treatment benefits. The most important attribute to both adults (<jats:italic>n<\/jats:italic>\u2009=\u2009201) and adolescents (<jats:italic>n<\/jats:italic>\u2009=\u2009120) was a 50% probability of achieving hair regrowth on most or all the scalp; however, adolescents placed greater relative importance on this attribute than did adults. Adults were averse to the risks of serious infection, cancer, and blood clots, whereas adolescents were averse to the risk of cancer. For a 20% increase in the probability of 80%\u2013100% scalp hair regrowth, adults were willing to accept a mean (95% confidence interval) 3\u2010year risk of serious infection, cancer, and blood clots of 7.4% (5.5\u20139.3), 2.5% (1.9\u20133.1), and 9.3% (6.4\u201312.2). Adolescents were willing to accept a 3\u2010year risk of cancer of 3.3% (2.4\u20134.2). Patients with AA in the US and Europe are willing to accept substantial risks to obtain an effective treatment.<\/jats:p>","DOI":"10.1111\/1346-8138.17056","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T06:56:06Z","timestamp":1702450566000},"page":"243-252","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment"],"prefix":"10.1111","volume":"51","author":[{"given":"Tommi","family":"Tervonen","sequence":"first","affiliation":[{"name":"Kielo Research  Zug Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Whichello","sequence":"additional","affiliation":[{"name":"Evidera Inc.  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Law","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Mauer","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debanjali","family":"Mitra","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Trapali","sequence":"additional","affiliation":[{"name":"Evidera Inc.  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Krucien","sequence":"additional","affiliation":[{"name":"Evidera Inc.  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3129-7268","authenticated-orcid":false,"given":"Brett","family":"Hauber","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"397","article-title":"Epidemiology and burden of alopecia areata: a systematic review","volume":"8","author":"Villasante Fricke AC","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.2013.4"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijt.ijt_99_20"},{"key":"e_1_2_8_5_1","first-page":"4","article-title":"Janus kinase and tyrosine kinase inhibitors in dermatology: a review of their utilization, safety profile and future applications","volume":"27","author":"Shalabi MMK","year":"2022","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2022.100156"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S334727"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.18.00013"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.006"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.008"},{"key":"e_1_2_8_12_1","unstructured":"US Food and Drug Administration.The Voice of the Patient. A series of reports from the U.S. Food and Drug Administration's (FDA's) Patient\u2010Focused Drug Development Initiative. Alopecia Areata 2018 [updated March 2018].https:\/\/www.fda.gov\/media\/112100\/download"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1697"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.673698"},{"key":"e_1_2_8_15_1","unstructured":"US Food and Drug Administration.Patient Preference Information \u2013 Voluntary Submission Review in Premarket Approval Applications Humanitarian Device Exemption Applications and De Novo Requests and Inclusion in Decision Summaries and Device Labeling. Guidance for Industry Food and Drug Administration Staff and Other Stakeholders 2016. [updated August 24 2016].https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/patient\u2010preference\u2010information\u2010voluntary\u2010submission\u2010review\u2010premarket\u2010approval\u2010applications"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.004"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.01.011"},{"key":"e_1_2_8_20_1","unstructured":"FDA.Guidance for industry. Formal meetings between the FDA and sponsors or applicants 2009 [cited 2023 09 Feb].https:\/\/www.fda.gov\/media\/72253\/download#:~:text=A%20Type%20C%20meeting%20is%20any%20meeting%20other days%20of%20FDA%20receipt%20of%20the%20written%20"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/10810730.2011.604383"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X0102100105"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00648-z"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key287"},{"issue":"2","key":"e_1_2_8_25_1","first-page":"66","article-title":"OP0032\u2009malignancies and serious infections in randomised controlled trials of janus kinase inhibitors in patients with rheumatoid arthritis: a systematic review and meta\u2010analysis","volume":"77","author":"Lopez\u2010Olivo MA","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826080-00004"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-018-0324-6"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-020-00475-y"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2017.1389648"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00133443"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.04.1822"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-010-9276-0_9"},{"key":"e_1_2_8_33_1","first-page":"105","volume-title":"Frontiers in econometrics","author":"McFadden D","year":"1973"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.2307\/1924536"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.1992.10475842"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.07.876"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-021-02286-z"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S309215"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T05:47:37Z","timestamp":1713419257000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.17056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/1346-8138.17056"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.17056","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"2023-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}